Almonertinib as Upfront Treatment for Uncommon EGFR Mutation Harboring Non-Small-Cell Lung Cancer Patients: A Multicenter, Open-Label, Phase II Trial
Latest Information Update: 08 May 2023
At a glance
- Drugs Aumolertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms AUTUMN
- 22 Sep 2020 New trial record